Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RIVASTIGMINE

All products: not a benefit

Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable

  • Donepezil (Aricept RDT): limited Use 347, 348, Not a benefit
  • Galantamine (Reminyl ER): limited Use 347, 348, Not a benefit

Mylan-Rivastigmine Patch 5 · DIN 02423413 · 9mg/5 Sq Cm · Trans Patch

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Rivastigmine Patch 5 · DIN 02423413 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-01-31 Health Canada: Marketed since 2016-12-05 · brand MYLAN-RIVASTIGMINE PATCH 5 · ATC N06DA03 RIVASTIGMINE · form Patch · route Transdermal · ingredients RIVASTIGMINE 4.6 MG/24HOUR · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90814 · Verify on the e-Formulary ↗ (DIN 02423413)

Source record
DIN 02423413: Mylan-Rivastigmine Patch 5 Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 120400035; group id 198; item number 0366; lccId None; manufacturer id MYL Source form: Trans Patch; strength: 9mg/5 Sq Cm Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $3.9773; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423413 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90814
Interchangeable products
Exelon Patch 5 · DIN 02302845 · not recorded Sandoz Rivastigmine Patch 5 · DIN 02426293 · not recorded
Shortage status: resolved shortage (ended 2026-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423413
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

DONEPEZIL HCL

· 48 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: dementia of the alzheimers type
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DONEPEZIL HCL · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) 1 INDICATIONS ARICEPT (donepezil hydrochloride) is indicated for: • symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00077966.PDF; date AUG 12, 1997; DIN 02232043; fetched 2026-09-10 Product monograph GALANTAMINE HYDROBROMIDE · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) Indications Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00085752.PDF; date 2026-08-11; DIN 02316943; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS EXELON® (rivastigmine hydrogen tartrate) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. • The symptomatic treatment of mild to moderate dementia in patients with idiopathic Parkinson’s disease, with onset at least 2 years after the initial diagnosis of Parkinson’s disease, and in whom other causes of dementia have been ruled out. EXELON® has not been studied in controlled clinical trials for longer than 6 months. EXELON® capsules and oral solution should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of dementia. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Dose escalation in patients >85 years old should proceed with caution. See 4.1 Dosing Considerations https://pdf.hres.ca/dpd_pm/00085220.PDF PM date: 2026-07-02 Source product: EXELON; DIN 02242115; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Mylan-Rivastigmine Patch 5: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026